March 20, 2020 / 9:20 PM / 18 days ago

BRIEF-Zealand Pharma Says Regains Worldwide Rights To Amylin Analog Program From Boehringer Ingelheim

March 20 (Reuters) - Zealand Pharma A/S:

* RETURNED A AMYLIN ANALOG THAT WAS BEING DEVELOPED FOR TREATMENT OF OBESITY AND TYPE 2 DIABETES.

* REGAINS WORLDWIDE RIGHTS TO AMYLIN ANALOG PROGRAM FROM BOEHRINGER INGELHEIM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below